Google
Trusted Resources: News & Events
Latest announcements and gatherings
Global Blood Therapeutics Receives EMA PRIME Designation for GBT440 for the Treatment of Sickle Cell Disease (SCD)
GBT440 is First Potential Treatment for SCD To Be Accepted for PRIME.
PRIME Designation Allows for Frequent and Early Interactions with the Agency Aimed at Assisting Accelerated Evaluation and ApprovalF.
Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that the European Medicines Agency (EMA) has determined that GBT440 for the treatment of sickle cell disease is eligible for its Priority Medicines (PRIME) program. The PRIME program is a new regulatory mechanism that provides for early and proactive EMA support to medicine developers to help patients benefit as early as possible from innovative new products that have demonstrated the potential to significantly address an unmet medical need.
+myBinderRelated Content
-
Access to Care for Individuals With Sickle Cell Anemia – SCDAASickle cell disease (SCD) is a genetic b...
-
Improving Quality of Care for Sickle Cell Patients in the Pediatric Emergency DepartmentOBJECTIVE: The aim of this study was to ...
-
Suvankar Majumdar, MDDr. Majumdar was born in Zambia, attende...
-
Dr. Nina AndersonDr. Nina Anderson, completed her doctora...
-
SCDAA News Advisory: Partial Hold on Gene Therapy TrialOn December 20, the FDA placed a partial...
-
CMO Speaks: Making ED Care Better for SCD – Progress in 2023Welcome to CMO Speaks, a blog featuring ...
-
Riley Hospital for Children at Indiana University HealthThe Cancer & Blood Diseases Departme...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.